HCTI Nasdaq Services-Computer Integrated Systems Design Financials FY2020βFY2025
Healthcare Triangle, Inc. had $13.9M of revenue in fiscal 2025, up 18.8% on the year before. Over five years, revenue changed β15.0% a year on average.
Last close Β· Oct 23, 2026
$0.34
11.4%Hi! I read Healthcare Triangle, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+18.8%
Yes. Sales grew 18.8% last year.
Does it make a profit?
β68.2%
No. It lost money last year.
Does profit turn into cash?
β119.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Healthcare Triangle, Inc. had $13.9M of revenue in fiscal 2025, up 18.8% on the year before. Over five years, revenue changed β15.0% a year on average. Its operating margin was β70.5%, down 29.8Β pts: of every 100 in sales, about β70 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Healthcare Triangle, Inc. lost $9.5M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$16.5M in fiscal 2025, β119.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Healthcare Triangle, Inc. owes $3.1M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Healthcare Triangle, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.8M | $1.3M | $1.2M | $0.0M | $7.6M |
| Debt incl. finance leases | $2.2M | $2.7M | $4.7M | $2.7M | $10.7M |
| Debt / equity | 0.2x | 0.4x | 8.7x | β | 1.1x |
| Interest coverage | β9.4x | β77.0x | β7.9x | β | β17.3x |
| Current ratio | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
| Quick ratio | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
| Total assets | $24.6M | $13.3M | $6.9M | $2.0M | $22.7M |
| Total liabilities | $8.5M | $7.2M | $8.2M | $7.1M | $12.8M |
| Shareholders' equity | $14.2M | $6.0M | $0.5M | β$5.1M | $9.9M |
| Net debt (β = net cash) | $0.4M | $1.3M | $3.4M | $2.6M | $3.1M |
KIRA Β· Its return on capital was β59.2%: every 100 invested in the business earned about β59 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Healthcare Triangle, Inc. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 3 / 9 | 3 / 9 | 4 / 9 | 3 / 9 |
| Accruals ratio | 27.8% | 6.5% | β47.6% | β65.0% | β110.9% | 57.1% |
| Altman Z'' | β | 1.43 | β11.34 | β22.98 | β91.66 | β8.14 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $31.3M | $35.3M | $45.9M | $33.2M | $11.7M | $13.9M |
| Net interest income | β | β$0.6M | β$0.2M | β$1.0M | β$1.2M | β$0.6M |
| Gross profit | $8.6M | $10.5M | $11.3M | $1.1B | $1.1B | $1.2B |
| Research and development | $1.7M | $5.3M | $8.1M | $0.8M | $0.4M | $0.5M |
| Operating income | $1.2M | β$5.4M | β$16.3M | β$7.7M | β$4.8M | β$9.8M |
| Interest expense | $0.1M | $0.6M | $0.2M | $1.0M | β | $0.6M |
| Pretax income | $2.6M | β$5.9M | β$13.9M | β$8.7M | β$6.0M | β$9.5M |
| Income tax | $0.3M | $0.0M | $0.5M | $0.0M | $0.0M | β |
| Net income | $2.4M | β$5.9M | β$14.4M | β$8.7M | β$6.0M | β$9.5M |
| Net income to common | $2.4M | β$6.0M | β$14.4M | β$8.7M | $6.0M | $9.4M |
| Diluted EPS | $0.08 | β$0.20 | β$3.88 | β$2.08 | β$16,909.30 | β$152.30 |
| Diluted shares | 0.03B | 0.03B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||
| Cash from operations | β$0.7M | β$7.1M | β$5.4M | β$2.2M | β$1.1M | β$16.5M |
| Capital expenditure | β | β | $0.0M | $0.0M | β | $0.0M |
| Free cash flow | β | β | β$5.4M | β$2.2M | β | β$16.5M |
| Depreciation and amortization | $0.8M | $1.4M | $2.9M | $1.6M | $0.9M | $0.7M |
| Stock-based compensation | β | $0.1M | $0.3M | $0.2M | $0.1M | $0.5M |
| Share buybacks | β | β | $0.1M | β | β | β |
| Dividends and buybacks | β | β | $0.1M | β | β | β |
| Balance sheet | ||||||
| Cash and short-term investments | $1.4M | $1.8M | $1.3M | $1.2M | $0.0M | $7.6M |
| Total debt | β | $2.2M | $2.7M | $4.7M | $2.7M | $10.7M |
| Current assets | $8.0M | $11.8M | $8.0M | $5.7M | $1.5M | $13.2M |
| Current liabilities | $6.8M | $6.3M | $6.6M | $8.2M | $7.1M | $12.8M |
| Property and equipment, net | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Goodwill | β | $1.3M | $1.3M | β | β | $2.9M |
| Intangible assets | $2.6M | $10.5M | $4.1M | $0.9M | β | $2.8M |
| Total assets | $11.1M | $24.6M | $13.3M | $6.9M | $2.0M | $22.7M |
| Total liabilities | $6.8M | $8.5M | $7.2M | $8.2M | $7.1M | $12.8M |
| Preferred stock | β | β | β | β | $7.4M | β |
| Shareholders' equity | $4.3M | $14.2M | $6.0M | $0.5M | β$5.1M | $9.9M |
| Margins | ||||||
| Gross margin | 27.4% | 29.8% | 24.6% | 3,222.6% | 9,148.4% | 8,890.6% |
| Operating margin | 3.8% | β15.2% | β35.6% | β23.2% | β40.6% | β70.5% |
| EBITDA margin | 6.3% | β11.2% | β29.2% | β18.5% | β33.0% | β65.4% |
| Net margin | 7.5% | β16.9% | β31.3% | β26.2% | β51.0% | β68.2% |
| FCF margin | β | β | β11.8% | β6.5% | β | β119.0% |
| Net interest share of revenue | β | β1.6% | β0.5% | β2.9% | β10.4% | β4.1% |
| Returns | ||||||
| Return on capital | β | β28.8% | β174.6% | β152.7% | β | β59.2% |
| Return on capital employed | 27.2% | β29.2% | β244.9% | 594.7% | 92.9% | β98.4% |
| Return on equity | 54.4% | β64.1% | β141.6% | β264.1% | β | β392.4% |
| Return on assets | 21.2% | β33.3% | β75.8% | β86.3% | β135.4% | β76.7% |
| Return on tangible equity | 137.7% | β238.6% | β2,155.9% | β | β | 225.0% |
| Growth | ||||||
| Revenue growth | β | 12.5% | 30.1% | β27.6% | β64.8% | 18.8% |
| Net income growth | β | β352.8% | β | β | β | β |
| EPS growth | β | β340.5% | β | β | β | β |
| Share count change | β | 5.5% | β87.4% | 13.0% | β100.0% | 15,375.0% |
| Financial health | ||||||
| Debt / equity | β | 0.2x | 0.4x | 8.7x | β | 1.1x |
| Interest coverage | 15.0x | β9.4x | β77.0x | β7.9x | β | β17.3x |
| Current ratio | 1.2x | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
| Quick ratio | 1.2x | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
| Capital allocation | ||||||
| Capex / revenue | β | β | 0.1% | 0.0% | β | 0.0% |
| Stock comp / revenue | β | 0.1% | 0.6% | 0.5% | 0.7% | 3.2% |
| Quality scores | ||||||
| Piotroski F-score | β | 2.0 | 3.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β | 1.4 | β11.3 | β23.0 | β91.7 | β8.1 |
| Accruals ratio | 27.8% | 6.5% | β47.6% | β65.0% | β110.9% | 57.1% |
Source: SEC EDGAR XBRL filings (CIK 0001839285). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
